[go: up one dir, main page]

HUP0400195A2 - Nátriumcsatornákat moduláló imidazolszármazékok, ezeket tartalmazó gyógyszerkészítmények és imidazolszármazékok alkalmazása nátriumcsatorna modulálására alkalmas gyógyszerkészítmények előállítására - Google Patents

Nátriumcsatornákat moduláló imidazolszármazékok, ezeket tartalmazó gyógyszerkészítmények és imidazolszármazékok alkalmazása nátriumcsatorna modulálására alkalmas gyógyszerkészítmények előállítására

Info

Publication number
HUP0400195A2
HUP0400195A2 HU0400195A HUP0400195A HUP0400195A2 HU P0400195 A2 HUP0400195 A2 HU P0400195A2 HU 0400195 A HU0400195 A HU 0400195A HU P0400195 A HUP0400195 A HU P0400195A HU P0400195 A2 HUP0400195 A2 HU P0400195A2
Authority
HU
Hungary
Prior art keywords
imidazole derivatives
pharmaceutical compositions
sodium channels
modulatig
group
Prior art date
Application number
HU0400195A
Other languages
English (en)
Inventor
Dennis Bigg
Anne-Marie Liberatore
Jacques Pommier
Original Assignee
Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) filed Critical Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)
Publication of HUP0400195A2 publication Critical patent/HUP0400195A2/hu
Publication of HUP0400195A3 publication Critical patent/HUP0400195A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Networks Using Active Elements (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Control Of Transmission Device (AREA)
  • Molds, Cores, And Manufacturing Methods Thereof (AREA)

Abstract

A találmány tárgyát nátriumcsatornákat moduláló új (I) általánosképletű imidazolszármazékok, és ezeket tartalmazó gyógyászatikészítmények képezik. Az (I) általános képletben - bizonyosmegkötésekkel R1 jelentése alkilcsoport vagy cikloalkilalkil-csoport,vagy adott esetben helyettesitett aralkilcsoport; R2 jelentése adottesetben helyettesített fenilcsoport, vagy adott esetben helyettesítettbifenilcsoport; R3 jelentése hidrogénatom vagy alkilcsoport; Atalálmány tárgyához tartoznak a fenti vegyületek sói, különösengyógyászati szempontból elfogadható sói. A találmány tárgya továbbá az(I) általános képletű - részben ismert - vegyületek alkalmazásanátriumcsatorna modulálására alkalmas gyógyszerkészítményekelőállítására. Ó
HU0400195A 2001-06-14 2002-06-14 Imidazole derivatives for modulatig sodium channels, pharmaceutical compositions containing them and use of imidazole derivatives for producing pharmaceutical compositions having sodium channels modulating effect HUP0400195A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107820A FR2825926A1 (fr) 2001-06-14 2001-06-14 Derives d'imidazoles modulant les canaux sodiques
PCT/FR2002/002039 WO2002102375A2 (fr) 2001-06-14 2002-06-14 Derives d'imidazoles modulant les canaux sodiques

Publications (2)

Publication Number Publication Date
HUP0400195A2 true HUP0400195A2 (hu) 2004-07-28
HUP0400195A3 HUP0400195A3 (en) 2004-10-28

Family

ID=8864329

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400195A HUP0400195A3 (en) 2001-06-14 2002-06-14 Imidazole derivatives for modulatig sodium channels, pharmaceutical compositions containing them and use of imidazole derivatives for producing pharmaceutical compositions having sodium channels modulating effect

Country Status (21)

Country Link
US (3) US7157483B2 (hu)
EP (1) EP1401432B1 (hu)
JP (1) JP2005500297A (hu)
KR (1) KR20040030672A (hu)
CN (1) CN1535148A (hu)
AT (1) ATE304354T1 (hu)
BR (1) BR0210285A (hu)
CA (1) CA2449916A1 (hu)
CZ (1) CZ297321B6 (hu)
DE (1) DE60206171T2 (hu)
DK (1) DK1401432T3 (hu)
ES (1) ES2249595T3 (hu)
FR (1) FR2825926A1 (hu)
HU (1) HUP0400195A3 (hu)
IS (1) IS2367B (hu)
MX (1) MXPA03011508A (hu)
NO (1) NO20035553D0 (hu)
NZ (1) NZ529741A (hu)
PL (1) PL366722A1 (hu)
RU (1) RU2296565C2 (hu)
WO (1) WO2002102375A2 (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004210711B2 (en) * 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
BRPI0416639A (pt) * 2003-11-19 2007-01-16 Metabasis Therapeutics Inc tiromiméticos contendo fósforo
AU2006249350B2 (en) 2003-11-19 2012-02-16 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
AU2006322844A1 (en) * 2005-12-07 2007-06-14 Ramot At Tel Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
US8247439B2 (en) * 2005-12-07 2012-08-21 Sepal Pharma Ltd. Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
US9284274B2 (en) 2005-12-07 2016-03-15 Ramot At Tel-Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
EP2114157B1 (en) 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
US7883898B2 (en) * 2007-05-07 2011-02-08 General Electric Company Method and apparatus for measuring pH of low alkalinity solutions
US8188080B2 (en) * 2007-10-17 2012-05-29 Sanford-Burnham Medical Research Institute VHR protein tyrosine phosphatase inhibitors, compositions and methods of use
US8815892B2 (en) 2008-03-25 2014-08-26 Affectis Pharmaceuticals Ag P2X7R antagonists and their use
EP2105164B1 (en) * 2008-03-25 2011-01-12 Affectis Pharmaceuticals AG Novel P2X7R antagonists and their use
KR101602985B1 (ko) * 2008-10-06 2016-03-11 시코쿠가세이고교가부시키가이샤 2-벤질-4-(2,4-디클로로페닐)-5-메틸이미다졸 화합물
US9284252B2 (en) 2009-06-09 2016-03-15 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
JP5368244B2 (ja) * 2009-10-14 2013-12-18 四国化成工業株式会社 ２−（２，４−ジクロロベンジル）−４−アリール−５−メチルイミダゾール化合物
JP5368263B2 (ja) * 2009-11-04 2013-12-18 四国化成工業株式会社 ４−（２，４−ジクロロフェニル）−５−メチルイミダゾール化合物
JP5368271B2 (ja) * 2009-11-20 2013-12-18 四国化成工業株式会社 ４−（４−ビフェニリル）−２−（２，４−ジクロロベンジル）イミダゾールおよび表面処理液
CN110198719A (zh) 2016-11-21 2019-09-03 维京治疗公司 治疗糖原贮积病的方法
KR102600115B1 (ko) 2017-06-05 2023-11-09 바이킹 테라퓨틱스 인코포레이티드 섬유증 치료를 위한 조성물
AU2019238090B2 (en) 2018-03-22 2024-08-01 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
CN120513089A (zh) * 2022-10-31 2025-08-19 Genep股份有限公司 作为钠通道抑制剂的咪唑化合物及其用途
WO2025231324A1 (en) * 2024-05-02 2025-11-06 Genep Inc. Imidazole compounds and their use as sodium channel inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1046248A (en) * 1962-08-02 1966-10-19 Benger Lab Ltd Substituted imidazoles
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
CN1093535C (zh) * 1994-09-26 2002-10-30 盐野义制药株式会社 咪唑衍生物
CN1284066A (zh) * 1997-12-04 2001-02-14 阿勒根销售公司 对α2B或2B/2C肾上腺素能受体具有激动剂样活性的取代咪唑衍生物
US6003118A (en) * 1997-12-16 1999-12-14 Acer Laboratories Inc. Method and apparatus for synchronizing clock distribution of a data processing system
ATE467620T1 (de) * 1999-03-26 2010-05-15 Euro Celtique Sa Arylsubstituierte pyrazole, imidazole, oxazole, thiazole und pyrrole, sowie deren verwendung
AR024077A1 (es) * 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
WO2001044201A1 (en) * 1999-12-16 2001-06-21 Schering Corporation Substituted imidazole neuropeptide y y5 receptor antagonists

Also Published As

Publication number Publication date
US7157483B2 (en) 2007-01-02
HUP0400195A3 (en) 2004-10-28
ATE304354T1 (de) 2005-09-15
US20040198792A1 (en) 2004-10-07
CN1535148A (zh) 2004-10-06
MXPA03011508A (es) 2004-03-18
US20060069146A1 (en) 2006-03-30
CA2449916A1 (fr) 2002-12-27
DE60206171D1 (de) 2005-10-20
DK1401432T3 (da) 2006-02-06
NZ529741A (en) 2006-10-27
FR2825926A1 (fr) 2002-12-20
US7402602B2 (en) 2008-07-22
IS7067A (is) 2003-12-08
RU2004100843A (ru) 2005-04-10
CZ297321B6 (cs) 2006-11-15
EP1401432B1 (fr) 2005-09-14
US20070099975A1 (en) 2007-05-03
RU2296565C2 (ru) 2007-04-10
DE60206171T2 (de) 2006-06-22
NO20035553D0 (no) 2003-12-12
BR0210285A (pt) 2004-06-29
KR20040030672A (ko) 2004-04-09
JP2005500297A (ja) 2005-01-06
WO2002102375A2 (fr) 2002-12-27
IS2367B (is) 2008-06-15
WO2002102375A3 (fr) 2003-09-25
PL366722A1 (en) 2005-02-07
CZ20033550A3 (cs) 2005-05-18
EP1401432A2 (fr) 2004-03-31
ES2249595T3 (es) 2006-04-01

Similar Documents

Publication Publication Date Title
HUP0400195A2 (hu) Nátriumcsatornákat moduláló imidazolszármazékok, ezeket tartalmazó gyógyszerkészítmények és imidazolszármazékok alkalmazása nátriumcsatorna modulálására alkalmas gyógyszerkészítmények előállítására
MXPA04000507A (es) Derivados de 1-fenilsulfonil-1,3-dihidro-2h-indol-2-ona, su preparacion y uso terapeutico.
MXPA05012247A (es) Derivados de bencimidazol nuevos.
SE0103836D0 (sv) Novel compounds
ATE316083T1 (de) Adamantanderivate
SE0200920D0 (sv) Novel compounds
SE0104140D0 (sv) Novel Compounds
PT1263725E (pt) Novos compostos
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
GB0124933D0 (en) Chemical compounds
AU2003228770A1 (en) Substituted pyrazolopyrimidines
ATE300541T1 (de) Pyrazolopyridinderivate
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
SE0302546D0 (sv) New compounds
HRP20050213A2 (en) 2,4-substituted indoles and their use as 5-ht6 modulators
DE602004031410D1 (de) Inden derivate als pharmazeutika
AP2002002466A0 (en) 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS.
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
MXPA04005484A (es) Procedimiento de preparacion de derivados de equinocandina.
DE60314381D1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
AU2002248531A1 (en) Pyrazolopyriadine derivatives
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
HUP0402033A2 (hu) 2-Amino-4-piridil-metil-tiazolin-származékok alkalmazása az indukálható NO-szintetáz inhibitoraként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
SE0202693D0 (sv) Compounds

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees